Related Experiment Videos
Common VKORC1 and GGCX polymorphisms associated with warfarin dose.
M Wadelius1, L Y Chen, K Downes
1Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden. mia.wadelius@medsci.uu.se
The Pharmacogenomics Journal
|May 11, 2005
Summary
Genetic factors in VKORC1 and GGCX significantly influence warfarin dosage, explaining nearly 60% of patient response variability. This finding supports personalized warfarin treatment strategies based on genetic profiles.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Genetics
Background:
- Warfarin is a critical anticoagulant medication with highly variable patient responses.
- Vitamin K epoxide reductase (VKORC1) and gamma-glutamyl carboxylase (GGCX) are key enzymes in the vitamin K cycle, essential for warfarin's mechanism of action.
- Suboptimal warfarin dosing, particularly early in treatment, increases risks of bleeding and thromboembolism.
Purpose of the Study:
- To investigate the combined impact of common polymorphisms in VKORC1 and GGCX on warfarin dose requirements.
- To determine the proportion of warfarin dose variability explained by these genetic factors.
Main Methods:
- Genotyping of 201 warfarin-treated patients for common single-nucleotide polymorphisms (SNPs) in VKORC1 and GGCX.
- Statistical analysis to assess the correlation between identified SNPs and required warfarin dosage.
Main Results:
- Five VKORC1 SNPs significantly correlated with warfarin dose, collectively explaining 29-30% of the dose variance.
- VKORC1 polymorphisms had a greater impact on warfarin dose than cytochrome P450 2C9 (12% variance).
- One GGCX SNP demonstrated a small but statistically significant effect on warfarin dose.
Conclusions:
- A novel combination of VKORC1 and GGCX genetic factors explains nearly 60% of variable warfarin response.
- Genotype-based warfarin dose prediction holds promise for enabling personalized anticoagulant therapy from treatment initiation.